NCT01898364 - Safety and Efficacy Evaluation of Repeat neoGAA Dosing in Late Onset Pompe Disease Patients. | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 19, 2013

Primary Completion Date

February 25, 2015

Study Completion Date

February 25, 2015

Conditions

Pompe DiseaseGlycogen Storage Disease Type II (GSD II)Acid Maltase Deficiency

Interventions

DRUG

GZ402666

Pharmaceutical form:lyophilized powder reconstituted for infusion Route of administration: intravenous

Trial Locations (17)

2100

Investigational Site Number 208001, København Ø

3000

Investigational Site Number 056001, Leuven

13385

Investigational Site Number 250001, Marseille

22030

Investigational Site Number 840003, Fairfax

27710

Investigational Site Number 840002, Durham

32209

Investigational Site Number 840010, Jacksonville

48149

Investigational Site Number 276002, Münster

55131

Investigational Site Number 276003, Mainz

63110

Investigational Site Number 840008, St Louis

75013

Investigational Site Number 250002, Paris

75390

Investigational Site Number 840009, Dallas

80336

Investigational Site Number 276001, München

85013

Investigational Site Number 840006, Phoenix

66160-7321

Investigational Site Number 840001, Kansas City

06012

Investigational Site Number 250003, Nice

3015 GJ

Investigational Site Number 528001, Rotterdam

NE1 4LP

Investigational Site Number 826003, Newcastle upon Tyne

All Listed Sponsors

lead

Genzyme, a Sanofi Company

INDUSTRY